Abstract
Trophoblast cell-surface antigen 2 (TROP2) is a type I transmembrane glycoprotein that is overexpressed in a number of cancer types, including triple-negative breast cancer. The current study aimed to develop a highly sensitive and specific monoclonal antibody (mAb) targeting TROP2, which could be used to evaluate TROP2 expression using flow cytometry, western blot analysis and immunohistochemistry by employing the Cell-Based Immunization and Screening (CBIS) method. The established anti-TROP2 mAb, TrMab-6 (mouse IgG2b, κ), detected TROP2 on PA-tagged TROP2-overexpressing Chinese hamster ovary-K1 (CHO/TROP2-PA) and breast cancer cell lines, including MCF7 and BT-474 using flow cytometry. Western blot analysis indicated a 40 kDa band in lysates prepared from CHO/TROP2-PA, MCF7 and BT-474 cells. Furthermore, TROP2 in 57/61 (93.4%) of the breast cancer specimens was strongly detected using immunohistochemical analysis with TrMab-6. In conclusion, the current study demonstrated that TrMab-6 may be a valuable tool for the detection of TROP2 in a wide variety of breast cancer types.
Highlights
Breast cancer is by far the most common malignant tumor in women
Radiotherapy, chemo‐ therapy, and molecular targeted therapies are currently used for breast cancer treatment; effective therapies for patients diagnosed with triple‐negative breast cancer [TNBC; i.e., those that are negative for estrogen receptor (ER), proges‐ terone receptor (PR), and human epidermal growth factor receptor 2 (HER2)] remain limited [2,3,4]
We immunized two mice with Chinese hamster ovary (CHO)/PA16‐Trophoblast cell‐surface antigen 2 (TROP2)‐RAP‐MAP cells and anti‐TROP2 monoclonal antibody (mAb) were screened via flow cytometry (Fig. 1)
Summary
Breast cancer is by far the most common malignant tumor in women. In 2018, there were 2,088,849 new breast cases (11.6% of the total cancer cases) and 626,679 deaths (6.6% of the total cancer deaths) worldwide [1]. TNBC accounts for ~15% of invasive breast cancers; it tends to be aggressive and is associated with a poor prognosis [2,5,6]. TNBC is more common in young women than in older women and is frequently associated with invasion and metastatic disease [2,5,6,7]. Highly sensitive and specific mono‐ clonal antibodies (mAbs) are required to facilitate the diagnosis of and treatment decisions for this breast cancer subtype
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
